We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $178M
1-Year Est. Return 118.43%
This Fund
S&P 500
This Quarter Est. Return
+19.81%
1 Year Est. Return
+118.43%
3 Year Est. Return
+79.96%
5 Year Est. Return
+93.71%
10 Year Est. Return
+781.26%
AUM
$178M
AUM Growth
+$20.2M
Cap. Flow
-$5.11M
Cap. Flow %
-2.87%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$206K
2
BIIB icon
Biogen
BIIB
+$182K

Top Sells

Rank Stock Value
1
INVA icon
Innoviva
INVA
+$5.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INVA icon
1
Innoviva
INVA
$1.53B
$42.9M 24.14%
1,890,604
-240,346
-11% -$5.5M
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$707M
$38.7M 21.75%
9,188,635
– –
AMRN
3
Amarin Corp
AMRN
$289M
$26.7M 15%
1,673,395
– –
NBIX icon
4
Neurocrine Biosciences
NBIX
$16B
$19.6M 11.04%
116,533
– –
CYTK icon
5
Cytokinetics
CYTK
$10.1B
$19.5M 10.95%
228,623
– –
LNTH icon
6
Lantheus
LNTH
$6.59B
$18.5M 10.41%
166,919
– –
BHVN icon
7
Biohaven
BHVN
$2.33B
$8.66M 4.87%
582,312
+19,128
+3% +$206K
REGN icon
8
Regeneron Pharmaceuticals
REGN
$85.9B
$2.61M 1.47%
4,190
– –
VOR icon
9
Vor Biopharma
VOR
$1.45B
$468K 0.26%
25,399
– –
BIIB icon
10
Biogen
BIIB
$32.6B
$205K 0.12%
+950
New +$182K

Similar funds

FC
FACT Capital New York $178M AUM 72.35% 1-Year Est. Return
RP
RIHO Partners Tucson, Arizona $178M AUM
BC
Bulwark Capital Fernandina Beach, Florida $178M AUM 11.44% 1-Year Est. Return
MG
Montaka Global Sydney $178M AUM
CSI
Cross Staff Investments Pittsford, New York $178M AUM 21.21% 1-Year Est. Return
SCS
Southern Capital Services Daphne, Alabama $178M AUM
NCG
Newport Capital Group Red Bank, New Jersey $178M AUM 12.73% 1-Year Est. Return
RE
Rydar Equities Weatherford, Texas $178M AUM 29.33% 1-Year Est. Return

Sarissa Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Sarissa Capital Management held 10 positions worth $178M, up 13% from $158M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management's Q2 2026 filing shows 1 new, 1 increased and 1 reduced positions. Its largest new stake was Biogen: 950 shares worth $205K. The largest sale was Innoviva, an estimated $5.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sarissa Capital Management's largest Q2 2026 buy was Biogen: 950 shares worth $205K.
  • Sarissa Capital Management added most to Biohaven in Q2 2026, an estimated $206K increase.
  • Sarissa Capital Management's biggest Q2 2026 reduction was Innoviva, cutting an estimated $5.5M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $178M portfolio in Q2 2026.
  • Sarissa Capital Management opened 1 new position and closed 0 in Q2 2026.
  • Sarissa Capital Management's portfolio value rose 13% quarter-over-quarter to $178M.

Based on Sarissa Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.